Tesamorelin in Thailand: Visceral Fat Reduction & Metabolic Therapy

The physician assessment for Tesamorelin candidacy includes reviewing baseline IGF-1 levels (to establish a safe starting point and monitor response), fasting glucose and HbA1c (Tesamorelin can modestly affect glucose handling), lipid panel, and any history of cancer, pituitary disease, or active medical conditions that would contraindicate GH-axis stimulation. IGF-1 is both a clinical biomarker for treatment response and a safety parameter: excessive elevation of IGF-1 is associated with increased cancer risk in observational data, which is why it is monitored regularly during the protocol.

Tesamorelin is not a general weight-loss peptide. It targets visceral fat specifically and works through the GH axis rather than the appetite and satiety pathways targeted by GLP-1 agents. Patients whose primary goal is overall weight loss rather than visceral fat reduction specifically may be better served by a different protocol. Discuss your goals with a physician to determine which approach best fits your clinical picture.

The FDA approval of Tesamorelin for HIV-associated lipodystrophy was based on two randomised, placebo-controlled, double-blind phase 3 trials demonstrating significant reductions in visceral adipose tissue area as measured by CT scan, alongside improvements in trunk fat and lipid parameters. The approval was granted in November 2010 to Theratechnologies. This regulatory history means Tesamorelin has a substantially more complete clinical evidence base than any other GHRH analogue, including published safety data from a regulatory submission.

For patients without HIV considering Tesamorelin for visceral fat or metabolic support, the investigational status means the evidence is mechanistic and derived from smaller studies and the HIV trial population, rather than from a dedicated phase 3 programme in a metabolic or non-HIV population. Physicians consider this evidence alongside the individual patient's clinical picture to make a prescribing decision. The stronger evidence base compared to other peptides is a legitimate factor in that assessment, but it does not change the requirement for physician oversight and individualised monitoring.

The GHRH receptor agonism shared by Tesamorelin and CJC-1295 means both peptides work through the same pituitary pathway, but their pharmacokinetic profiles differ substantially. Tesamorelin has a very short half-life (minutes) and is administered daily to produce a physiological GH pulse each evening. CJC-1295 with DAC has a half-life measured in days, producing a more sustained baseline elevation of GH rather than a single daily pulse. Whether pulsatile or sustained GH elevation is preferable for a given clinical goal is a legitimate subject of physician assessment.

Ipamorelin's ghrelin receptor mechanism is complementary rather than overlapping with GHRH receptor agonism: the two pathways act on different pituitary cell populations and can be combined to produce additive GH release. This is why CJC-1295 and Ipamorelin are commonly used together. Tesamorelin is not typically combined with Ipamorelin in the same way, partly because Tesamorelin already has a well-defined dose and partly because the FDA-approved protocol is a standalone daily injection. The physician will assess whether a combined or standalone protocol is more appropriate given the patient's specific clinical goals. Discuss your options in a consultation.

The monitoring approach for Tesamorelin is more structured than for some other peptides because IGF-1 provides a direct, quantifiable biomarker of pharmacological activity. An IGF-1 level that rises above the age-adjusted upper limit of normal indicates the dose is producing supraphysiological GH stimulation and should be reduced. This makes Tesamorelin a relatively well-monitored peptide in clinical practice: the physician has an objective blood test to guide dosing rather than relying only on symptom reports and physical measurements.

Patients should expect a gradual rather than rapid change in body composition. In the phase 3 HIV trials, the primary CT-measured visceral fat reduction was statistically significant by week 8 and reached its peak by week 26. In clinical practice outside trials, the timeline and magnitude of response vary based on baseline visceral fat, dose, adherence, and individual metabolic factors. The physician will discuss realistic expectations at the initial consultation and reassess response at each scheduled review. Book a consultation to understand what the protocol would look like for your specific situation.

Visceral adipose tissue (VAT) wraps around the abdominal organs and is drained by the portal circulation directly into the liver, where free fatty acids and inflammatory signals from visceral fat have direct metabolic effects on hepatic glucose production, lipid metabolism, and insulin sensitivity. This anatomical position means visceral fat has a disproportionate effect on metabolic health relative to its volume: individuals with high VAT but relatively normal total body weight have significantly elevated metabolic and cardiovascular risk compared to individuals with the same total body fat distributed primarily subcutaneously.

Tesamorelin's selective reduction of visceral fat is mechanistically explained by the higher density of GH receptors in visceral adipocytes compared to subcutaneous adipocytes: the same increase in GH and IGF-1 produces a proportionally greater lipolytic response in visceral fat. This selectivity is clinically important because general weight loss interventions reduce both visceral and subcutaneous fat without specificity, whereas Tesamorelin's GH-mediated mechanism preferentially addresses the metabolically active visceral compartment.

The downstream metabolic effects observed in Tesamorelin clinical trials, including improvements in triglycerides and in some cases modest improvements in glucose metabolism, are consistent with the known metabolic consequences of reducing visceral fat specifically rather than fat in general. Patients with metabolic syndrome characterised by central adiposity, elevated triglycerides, reduced HDL, and glucose impairment are a population where physician-supervised Tesamorelin use may address the metabolically active fat depot that is driving their risk profile. This requires physician assessment to confirm that the GH-axis mechanism is appropriate given the patient's glucose status and overall metabolic picture.

Tesamorelin is not available as an over-the-counter supplement or as a self-administered research peptide through this clinic. The GH-axis mechanism requires clinical monitoring, and the specific requirement to track IGF-1 levels is a safety parameter that cannot be managed responsibly without access to blood testing. Patients who self-source Tesamorelin and self-dose without physician oversight cannot confirm whether their IGF-1 is within the safe range, cannot adjust the dose appropriately, and cannot identify early signs of adverse effects that require clinical attention.

For patients who have used GH-related peptides previously and are familiar with the monitoring requirements, the physician assessment at Peptides Thailand involves reviewing that prior history, including what IGF-1 results were achieved and what dose was used. This context helps the physician individualize the starting dose and monitoring frequency. For patients new to GH-axis peptides, the consultation will cover the mechanism, what to expect from the protocol, and the full monitoring plan before any prescription is issued. Book a consultation to begin the assessment process.